{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:19:36Z","timestamp":1771611576559,"version":"3.50.1"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P024351\/1"],"award-info":[{"award-number":["MR\/P024351\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00830","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T04:16:08Z","timestamp":1524456968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting Head and Neck Cancer by Vaccination"],"prefix":"10.3389","volume":"9","author":[{"given":"Chuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Dickie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhcha V.","family":"Sutavani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Pointer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Savelyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.oraloncology.2010.02.015","article-title":"Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival","volume":"46","author":"Warnakulasuriya","year":"2010","journal-title":"Oral Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","article-title":"Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers","volume":"31","author":"Chaturvedi","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7314\/APJCP.2014.15.2.537","article-title":"Head and neck cancer: global burden and regional trends in India","volume":"15","author":"Mishra","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B5","first-page":"38","volume-title":"Cancer Incidence in Peninsular Malaysia, 2003\u20132005","author":"Chye","year":"2008"},{"key":"B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1055-9965.EPI-08-0347","article-title":"Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International head and neck cancer epidemiology consortium","volume":"18","author":"Hashibe","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-017-0879-4","article-title":"Immunotherapy in head and neck cancer: aiming at EXTREME precision","volume":"15","author":"Szturz","year":"2017","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor Activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"B10","first-page":"567","article-title":"Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence","volume":"5","author":"Franceschi","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D\u2019Souza","year":"2007","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1002\/ijc.24994","article-title":"The role of human papillomavirus in the increased incidence of base of tongue cancer","volume":"126","author":"Attner","year":"2010","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1758-3284-1-36","article-title":"HPV & head and neck cancer: a descriptive update","volume":"1","author":"Goon","year":"2009","journal-title":"Head Neck Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.1158\/0008-5472.CAN-16-0633","article-title":"HPV-related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology","volume":"76","author":"Schache","year":"2016","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S3\/1","DOI":"10.1016\/j.vaccine.2006.05.115","article-title":"Chapter 1: HPV in the etiology of human cancer","volume":"24","author":"Munoz","year":"2006","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/14737140.2015.957189","article-title":"The role of sexual behavior in head and neck cancer: implications for prevention and therapy","volume":"15","author":"Rettig","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1128\/JVI.77.3.2021-2028.2003","article-title":"Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA","volume":"77","author":"Bechtold","year":"2003","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.virol.2013.06.006","article-title":"The papillomavirus E2 proteins","volume":"445","author":"McBride","year":"2013","journal-title":"Virology"},{"key":"B20","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1128\/JVI.67.10.6170-6178.1993","article-title":"The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein","volume":"67","author":"Conrad","year":"1993","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.virol.2010.09.015","article-title":"1st International workshop on papillomavirus E5 oncogene-a report","volume":"408","author":"Borzacchiello","year":"2010","journal-title":"Virology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/etm.2013.1374","article-title":"Human papillomavirus oncoproteins and apoptosis (review)","volume":"7","author":"Jiang","year":"2014","journal-title":"Exp Ther Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0168-1702(02)00190-9","article-title":"Human papillomavirus immortalization and transformation functions","volume":"89","author":"Munger","year":"2002","journal-title":"Virus Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/S0140-6736(05)67725-2","article-title":"Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors","volume":"366","author":"Danaei","year":"2005","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.otohns.2004.02.035","article-title":"Habitual risk factors for head and neck cancer","volume":"131","author":"Goldenberg","year":"2004","journal-title":"Otolaryng Head Neck"},{"key":"B26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Lawrence","year":"2015","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41199-016-0003-z","article-title":"Genomic insights into head and neck cancer","volume":"1","author":"Beck","year":"2016","journal-title":"Cancers Head Neck"},{"key":"B29","unstructured":"Cervarix2009"},{"key":"B30","unstructured":"Gardasil2011"},{"key":"B31","unstructured":"Gardasil 92014"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination","volume":"4","author":"Frazer","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI28607","article-title":"Prophylactic human papillomavirus vaccines","volume":"116","author":"Lowy","year":"2006","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"B35","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1002","DOI":"10.1002\/cti2.1002","article-title":"A vaccine to prevent cervical cancer: academic and industrial collaboration and a Lasker award","volume":"7","author":"Scolnick","year":"2018","journal-title":"Clin Transl Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.4161\/hv.29475","article-title":"Overexpressed oncogenic tumor-self antigens","volume":"10","author":"Bright","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11895","DOI":"10.1073\/pnas.1006500107","article-title":"Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses","volume":"107","author":"Welters","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-013-1499-2","article-title":"The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study","volume":"63","author":"de Vos van Steenwijk","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","article-title":"Vaccination against oncoproteins of HPV16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T-cell response","volume":"22","author":"van Poelgeest","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1007\/s12105-012-0372-5","article-title":"HPV detection methods in head and neck cancer","volume":"6","author":"Venuti","year":"2012","journal-title":"Head Neck Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.molimm.2014.12.007","article-title":"A novel \u201cpriming-boosting\u201d strategy for immune interventions in cervical cancer","volume":"64","author":"Liao","year":"2015","journal-title":"Mol Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11596-013-1189-5","article-title":"HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo","volume":"33","author":"Liao","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/21645515.2017.1264777","article-title":"HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy","volume":"13","author":"Paolini","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00262-015-1734-0","article-title":"Immunotherapy of HPV-associated cancer: DNA\/plant-derived vaccines and new orthotopic mouse models","volume":"64","author":"Venuti","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.3390\/v7092860","article-title":"Recent progress in therapeutic treatments and screening strategies for the prevention and treatment of HPV-associated head and neck cancer","volume":"7","author":"Whang","year":"2015","journal-title":"Viruses"},{"key":"B54","first-page":"g2","article-title":"Evidence of Epstein-Barr virus association with head and neck cancers: a review","volume":"82","author":"Prabhu","year":"2016","journal-title":"J Can Dent Assoc"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113702","article-title":"Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers","volume":"9","author":"Deng","year":"2014","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"27328","DOI":"10.18632\/oncotarget.16033","article-title":"Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas","volume":"8","author":"Turunen","year":"2017","journal-title":"Oncotarget"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","article-title":"The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up","volume":"64","author":"Si","year":"2016","journal-title":"Chem Pharm Bull"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.oraloncology.2013.09.009","article-title":"Promising systemic immunotherapies in head and neck squamous cell carcinoma","volume":"49","author":"Gildener-Leapman","year":"2013","journal-title":"Oral Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carbone","year":"2005","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/0008-5472.CAN-07-3095","article-title":"Epitope landscape in breast and colorectal cancer","volume":"68","author":"Segal","year":"2008","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.oraloncology.2016.09.010","article-title":"Neoantigens in immunotherapy and personalized vaccines: implications for head and neck squamous cell carcinoma","volume":"71","author":"Zolkind","year":"2017","journal-title":"Oral Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-1426-1-11","article-title":"Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors","volume":"1","author":"Overwijk","year":"2013","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-15-2507","article-title":"Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunologic and clinical outcomes","volume":"22","author":"McCann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-13-2617","article-title":"Phase I dendritic cell p53 peptide vaccine for head and neck cancer","volume":"20","author":"Schuler","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1349-7006.2010.01789.x","article-title":"Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer","volume":"102","author":"Miyazaki","year":"2011","journal-title":"Cancer Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1084\/jem.20031677","article-title":"Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters","volume":"199","author":"Gotter","year":"2004","journal-title":"J Exp Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mrd.1080380215","article-title":"Analysis of mRNA for class I HLA on human gametogenic cells","volume":"38","author":"Janitz","year":"1994","journal-title":"Mol Reprod Dev"},{"key":"B73","first-page":"19","article-title":"Cancer is a somatic cell pregnancy","volume":"7","author":"Old","year":"2007","journal-title":"Cancer Immun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.4049\/jimmunol.0900903","article-title":"Characterization of preexisting MAGE-A3-specific CD4(+) T cells in cancer patients and healthy individuals and their activation by protein vaccination","volume":"183","author":"Tsuji","year":"2009","journal-title":"J Immunol"},{"key":"B76","first-page":"1743","article-title":"Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity","volume":"62","author":"Valmori","year":"2002","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/hed.10223","article-title":"Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma","volume":"25","author":"Kienstra","year":"2003","journal-title":"Head Neck"},{"key":"B78","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.oraloncology.2012.08.005","article-title":"PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions","volume":"49","author":"Szczepanski","year":"2013","journal-title":"Oral Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2","article-title":"Expression of SSX genes in human tumors","volume":"77","author":"Tureci","year":"1998","journal-title":"Int J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/1535-7163.MCT-14-0796","article-title":"A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels MAGEA3\/6 as a marker for recurrence","volume":"14","author":"Zamuner","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/hed.22004","article-title":"inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma","volume":"34","author":"Voskens","year":"2012","journal-title":"Head Neck"},{"key":"B82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/intimm\/dxw027","article-title":"The present status and future prospects of peptide-based cancer vaccines","volume":"28","author":"Hirayama","year":"2016","journal-title":"Int Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3892\/ijo.28.6.1375","article-title":"Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas","volume":"28","author":"Yamabuki","year":"2006","journal-title":"Int J Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/j.1349-7006.2007.00603.x","article-title":"Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy","volume":"98","author":"Suda","year":"2007","journal-title":"Cancer Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1479-5876-10-141","article-title":"Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens","volume":"10","author":"Kono","year":"2012","journal-title":"J Transl Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/j.1349-7006.2009.01200.x","article-title":"Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer","volume":"100","author":"Kono","year":"2009","journal-title":"Cancer Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1078-0432.CCR-14-0202","article-title":"Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS","volume":"21","author":"Yoshitake","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nature25442","article-title":"Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling","volume":"553","author":"Pasqual","year":"2018","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1074-7613(94)80017-0","article-title":"Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides","volume":"1","author":"Alexander","year":"1994","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/3266","article-title":"DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma","volume":"4","author":"King","year":"1998","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/90816","article-title":"Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies","volume":"19","author":"Savelyeva","year":"2001","journal-title":"Nat Biotechnol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/emm.2007.74","article-title":"DNA vaccines for cervical cancer: from bench to bedside","volume":"39","author":"Hung","year":"2007","journal-title":"Exp Mol Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"14646","DOI":"10.1073\/pnas.0404896101","article-title":"DNA vaccines to attack cancer","volume":"101","author":"Stevenson","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc2326","article-title":"DNA vaccines: precision tools for activating effective immunity against cancer","volume":"8","author":"Rice","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4161\/onci.20426","article-title":"Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001","volume":"1","author":"Inderberg-Suso","year":"2012","journal-title":"Onco-immunology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"E686","DOI":"10.1073\/pnas.1713607115","article-title":"Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses","volume":"115","author":"Choi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B100","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.virol.2015.03.013","article-title":"Innate immune recognition of DNA: a recent history","author":"Dempsey","year":"2015","journal-title":"Virology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1089\/hum.2009.067","article-title":"DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer","volume":"20","author":"Low","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/82_2015_431","article-title":"Tapping the potential of DNA delivery with electroporation for cancer immunotherapy","volume":"405","author":"Kraynyak","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1285477","article-title":"Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma","volume":"13","author":"Meleshko","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of different vaccine delivery systems for cancer therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0264-410X(96)00117-X","article-title":"Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer","volume":"14","author":"Boursnell","year":"1996","journal-title":"Vaccine"},{"key":"B110","first-page":"1869","article-title":"Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells","volume":"9","author":"Pim","year":"1994","journal-title":"Oncogene"},{"key":"B111","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/2051-1426-3-S2-P426","article-title":"Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results","volume":"3","author":"Aggarwal","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1172\/JCI200112346","article-title":"Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen","volume":"108","author":"Cheng","year":"2001","journal-title":"J Clin Invest"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1016\/j.vaccine.2009.07.005","article-title":"Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery","volume":"27","author":"Best","year":"2009","journal-title":"Vaccine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","article-title":"A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"140","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-2111-y","article-title":"Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model","volume":"67","author":"Allen","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B116","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/82_2017_509","article-title":"mRNA cancer vaccines-messages that prevail","volume":"405","author":"Grunwitz","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"334ra52","DOI":"10.1126\/scitranslmed.aad8307","article-title":"Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses","volume":"8","author":"Welters","year":"2016","journal-title":"Sci Transl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e14030","DOI":"10.1200\/jco.2015.33.15_suppl.e14030","article-title":"Phase I\/IIa trial targeting p16(INK4a) by peptide vaccination in patients with human papillomavirus-associated cancer","volume":"33","author":"Reuschenbach","year":"2015","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"TPS3113","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3113","article-title":"A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant","volume":"34","author":"Slingerland","year":"2016","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3390\/v6062392","article-title":"Alphavirus-based vaccines","volume":"6","author":"Lundstrom","year":"2014","journal-title":"Viruses"},{"key":"B123","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2008.00670.x","article-title":"Host responses to alphavirus infection","volume":"225","author":"Ryman","year":"2008","journal-title":"Immunol Rev"},{"key":"B124","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/135965350400900515","article-title":"Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization","volume":"9","author":"Daemen","year":"2004","journal-title":"Antivir Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1525-0016(03)00238-7","article-title":"Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles","volume":"8","author":"Lin","year":"2003","journal-title":"Mol Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.gt.3302536","article-title":"Induction of human papilloma virus E6\/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6\/E7-transgenic mice","volume":"12","author":"Riezebos-Brilman","year":"2005","journal-title":"Gene Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine"},{"key":"B128","first-page":"5792","article-title":"Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice","volume":"62","author":"Eiben","year":"2002","journal-title":"Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"B130","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B131","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B133","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"B134","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1128\/JVI.79.16.10397-10407.2005","article-title":"Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor","volume":"79","author":"Chahroudi","year":"2005","journal-title":"J Virol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40661-017-0047-8","article-title":"Therapeutic options for treatment of human papillomavirus-associated cancers \u2013 novel immunologic vaccines: ADXS11-001","volume":"4","author":"Miles","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"B137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40661-017-0046-9","article-title":"Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy","volume":"4","author":"Miles","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"B138","doi-asserted-by":"publisher","first-page":"am2016-lb-095","DOI":"10.1158\/1538-7445.AM2016-LB-095","article-title":"Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity","volume":"76","author":"Krupar","year":"2016","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","article-title":"Whole cell vaccines\u2014past progress and future strategies","author":"Keenan","year":"2012","journal-title":"Semin Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.3390\/ijms160510578","article-title":"Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system","volume":"16","author":"Lathuiliere","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1058P","DOI":"10.1093\/annonc\/mdw378.12","article-title":"MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology","volume":"27","author":"Mach","year":"2016","journal-title":"Ann Oncol"},{"key":"B142","unstructured":"Immunovative Therapies Ltd2015"},{"key":"B143","doi-asserted-by":"publisher","first-page":"701657","DOI":"10.1155\/2010\/701657","article-title":"Immune suppression in head and neck cancers: a review","volume":"2010","author":"Duray","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/0008-5472.CAN-15-3121","article-title":"Upregulated glucose metabolism correlates inversely with CD8+ T-cell infiltration and survival in squamous cell carcinoma","volume":"76","author":"Ottensmeier","year":"2016","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jnci\/djx121","article-title":"Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4","volume":"110","author":"Hanley","year":"2018","journal-title":"J Natl Cancer Inst"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T17:29:23Z","timestamp":1661016563000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":146,"alternative-id":["10.3389\/fimmu.2018.00830"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00830","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"article-number":"830"}}